These include the identification of more aggressive vs indolent cancers, the treatment of inherently difficult subtypes such as triple negative breast cancer (TNBC; ERα, PR negative, HER2 not overexpressed), de novo and acquired resistance to therapy causing therapeutic failure during adjuvant therapy and, finally, treatment of metastatic disease. This evidence concerns the gene ERBB2 and cancer.